JP2015504430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504430A5 JP2015504430A5 JP2014542299A JP2014542299A JP2015504430A5 JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5 JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- allele
- seq
- patient
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000013691 Interleukin-17 Human genes 0.000 claims 41
- 108700028369 Alleles Proteins 0.000 claims 35
- 239000005557 antagonist Substances 0.000 claims 30
- 239000012472 biological sample Substances 0.000 claims 11
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 9
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 6
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000003556 assay Methods 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 2
- 239000000710 homodimer Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 2
- 238000003757 reverse transcription PCR Methods 0.000 claims 2
- 238000000123 temperature gradient gel electrophoresis Methods 0.000 claims 2
- 101710099953 DNA mismatch repair protein msh3 Proteins 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 1
- 108010052199 HLA-C Antigens Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 210000003608 fece Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002731 protein assay Methods 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000001179 synovial fluid Anatomy 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ370/2011 | 2011-11-21 | ||
| IQ3702011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 | |
| US61/624,564 | 2012-04-16 | ||
| PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504430A JP2015504430A (ja) | 2015-02-12 |
| JP2015504430A5 true JP2015504430A5 (enExample) | 2015-07-23 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542299A Pending JP2015504430A (ja) | 2011-11-21 | 2012-06-07 | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (enExample) |
| EP (1) | EP2783014A1 (enExample) |
| JP (1) | JP2015504430A (enExample) |
| KR (1) | KR20140097178A (enExample) |
| CN (1) | CN104011223A (enExample) |
| AR (1) | AR086907A1 (enExample) |
| AU (1) | AU2012341081B2 (enExample) |
| BR (1) | BR112014012101A2 (enExample) |
| CA (1) | CA2856252A1 (enExample) |
| MX (1) | MX2014006158A (enExample) |
| RU (1) | RU2014125071A (enExample) |
| WO (1) | WO2013077907A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SI3757126T1 (sl) | 2010-11-05 | 2025-12-31 | Novartis Ag | Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17 |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3682905T3 (pl) | 2011-10-03 | 2022-04-04 | Modernatx, Inc. | Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania |
| PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| JP2017521479A (ja) | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP2017528465A (ja) * | 2014-09-10 | 2017-09-28 | ノバルティス アーゲー | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用 |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016118921A1 (en) * | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
| JP6931648B2 (ja) | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| IL283192B2 (en) * | 2018-11-20 | 2025-10-01 | Janssen Biotech Inc | A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody |
| AU2020288749A1 (en) * | 2019-06-04 | 2022-02-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody |
| CN114981302A (zh) * | 2019-09-20 | 2022-08-30 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗自身免疫性疾病的方法 |
| EP4305062A1 (en) * | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
| CA3212729A1 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PL1963368T6 (pl) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US20100239590A1 (en) * | 2007-06-20 | 2010-09-23 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| IN2012DN00767A (enExample) * | 2009-07-28 | 2015-06-26 | Janssen Biotech Inc | |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
-
2012
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504430A5 (enExample) | ||
| RU2014125071A (ru) | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa | |
| RU2014146594A (ru) | Способы лечения анкилозирующего спондилита с использованием антагонистов il-17 | |
| US12269873B2 (en) | Signature of TL1A (TNFSF15) signaling pathway | |
| JP2017513937A5 (enExample) | ||
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| US20100316608A1 (en) | Method of Determining A Response To Treatment With Immunomodulatory Composition | |
| CA2714410A1 (en) | Disease markers and uses thereof | |
| JP2009039107A5 (enExample) | ||
| van Sorge et al. | Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms | |
| JP2017519498A5 (enExample) | ||
| WO2016022589A2 (en) | Methods for treating multiple myeloma | |
| EP3390449A1 (en) | Antibodies to risperidone and use thereof | |
| CN102808030B (zh) | 单核苷多态性rs3888188在检测结核病易感性中的应用 | |
| Bojarojc-Nosowicz et al. | Polymorphism and expression of the tumour necrosis factor-alpha (TNF-alpha) gene in non-infected cows and in cows naturally infected with the bovine leukaemia virus (BLV). | |
| WO2011146985A1 (en) | Method of determining response to treatment with immunomodulatory composition | |
| US20210148910A1 (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
| US20100092468A1 (en) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents | |
| JP2019520355A5 (enExample) | ||
| WO2013107005A1 (zh) | 人稀有血型的多重pcr检测方法和试剂盒 | |
| KR20070004082A (ko) | Ｆｃ 수용체 다형성의 확인을 위한 핵산 기반 분석 | |
| Jiao et al. | Gene analysis of two cases with CisAB/B blood subgroup | |
| KR20220061425A (ko) | 항암제 반응성 예측용 바이오마커 및 이의 용도 | |
| US20180258475A1 (en) | Method and device for snp genotyping | |
| Parasannanavar et al. | HLA-DRβ1* 04 typing by simple in-house PCR-SSP technique for rheumatoid arthritis patients |